194 related articles for article (PubMed ID: 24947923)
1. Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.
Li J; Kim S; Sha X; Wiegand R; Wu J; LoRusso P
Clin Cancer Res; 2014 Aug; 20(15):3931-44. PubMed ID: 24947923
[TBL] [Abstract][Full Text] [Related]
2. A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
Stodtmann S; Nuthalapati S; Eckert D; Kasichayanula S; Joshi R; Bach BA; Mensing S; Menon R; Xiong H
J Clin Pharmacol; 2021 Sep; 61(9):1195-1205. PubMed ID: 33894017
[TBL] [Abstract][Full Text] [Related]
3. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).
Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM
J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511
[TBL] [Abstract][Full Text] [Related]
4. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
Niu J; Scheuerell C; Mehrotra S; Karan S; Puhalla S; Kiesel BF; Ji J; Chu E; Gopalakrishnan M; Ivaturi V; Gobburu J; Beumer JH
J Clin Pharmacol; 2017 Aug; 57(8):977-987. PubMed ID: 28387939
[TBL] [Abstract][Full Text] [Related]
5. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase.
Li X; Delzer J; Voorman R; de Morais SM; Lao Y
Drug Metab Dispos; 2011 Jul; 39(7):1161-9. PubMed ID: 21436403
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies.
Salem AH; Giranda VL; Mostafa NM
Clin Pharmacokinet; 2014 May; 53(5):479-88. PubMed ID: 24452810
[TBL] [Abstract][Full Text] [Related]
7. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Singh R; Mehrotra S; Gopalakrishnan M; Gojo I; Karp JE; Greer JM; Chen A; Piekarz R; Kiesel BF; Gobburu J; Rudek MA; Beumer JH;
Cancer Chemother Pharmacol; 2019 Feb; 83(2):319-328. PubMed ID: 30456480
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.
Nuthalapati S; Munasinghe W; Giranda V; Xiong H
Clin Pharmacokinet; 2018 Jan; 57(1):51-58. PubMed ID: 28497258
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.
Mehrotra S; Gopalakrishnan M; Gobburu J; Greer JM; Piekarz R; Karp JE; Pratz K; Rudek MA
Br J Clin Pharmacol; 2017 Aug; 83(8):1688-1700. PubMed ID: 28156017
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
Neul C; Hofmann U; Schaeffeler E; Winter S; Klein K; Giacomini KM; Eichelbaum M; Schwab M; Nies AT
Br J Pharmacol; 2021 Mar; 178(6):1459-1474. PubMed ID: 33434947
[TBL] [Abstract][Full Text] [Related]
13. Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
Gueorguieva I; Jackson K; Wrighton SA; Sinha VP; Chien JY
Br J Clin Pharmacol; 2010 Oct; 70(4):523-36. PubMed ID: 20840444
[TBL] [Abstract][Full Text] [Related]
14. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
Munasinghe W; Stodtmann S; Tolcher A; Calvo E; Gordon M; Jalving M; de Vos-Geelen J; Medina D; Bergau D; Nuthalapati S; Hoffman D; Shepherd S; Xiong H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1003-1011. PubMed ID: 27709282
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes.
Song IS; Shin HJ; Shin JG
Xenobiotica; 2008 Sep; 38(9):1252-62. PubMed ID: 18728938
[TBL] [Abstract][Full Text] [Related]
16. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
Müller F; Weitz D; Mertsch K; König J; Fromm MF
Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α2A-adrenoreceptor agonist.
Li X; Sun X; Chen J; Lu Y; Zhang Y; Wang C; Li J; Zhang Q; Zhao D; Chen X
Xenobiotica; 2015 Jan; 45(1):88-94. PubMed ID: 25115365
[TBL] [Abstract][Full Text] [Related]
19. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
